New Target for Cancer Immunotherapy

A research team from Massachusetts General Hospital has identified a significant target for immune-oncology therapy-tumor necrosis factor receptor type II (TNFR2). The inhibition of these receptors was found to induce the immune system of cancer patients to fight against the developing tumor.
Email bookmark
Font : A-A+

Related Links